2-叔丁氧基-5-氟苯胺 | 862594-16-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-叔丁氧基-5-氟苯胺
• 英文名称: 2-tert-butoxy-5-fluoroaniline
• 英文别名: 2-tert-butoxy-5-fluoro-phenylamine；5-fluoro-2-[(2-methylpropan-2-yl)oxy]aniline
• CAS: 862594-16-9
• 化学式: C₁₀H₁₄FNO
• 分子量: 183.226
• InChiKey: TZPORLMVZKVDQL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-叔丁氧基-5-氟苯胺 在 叔丁基锂 、 氯甲酸乙酯 、 三乙胺 作用下， 以 四氢呋喃 、 氯仿 、 甲苯 、 正戊烷 为溶剂， 反应 2.5h， 生成 2-isopropoxy-7-butoxybenzothiazole
  参考文献：
  名称：

  Synthesis of the Marine Sponge Derived β₂-Adrenoceptor Agonist S1319

  摘要：

  The marine sponge derived beta 2-adrenoceptor agonist S1319 has been synthesized following a six-step linear sequence. Central to the approach employed is the formation of a 7-lithiated-2,4-dialkoxybenzothiazole intermediate obtained via a directed-lithiation/benzyne-mediated cyclization reaction. The incorporation of a tert-butyl ether residue into the cyclization precursor for the pivotal ring-closing step has been shown to significantly increase the efficiency of the reaction by the suppression of a competing directed ortho-lithiation reaction.

  DOI：

  10.1021/ol0518840
• 作为产物：
  描述：

  1-叔丁氧基-4-氟-2-硝基苯 在 platinum(IV) oxide 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、101.32 kPa 条件下， 反应 18.0h， 以96%的产率得到2-叔丁氧基-5-氟苯胺
  参考文献：
  名称：

  Synthesis of the Marine Sponge Derived β₂-Adrenoceptor Agonist S1319

  摘要：

  The marine sponge derived beta 2-adrenoceptor agonist S1319 has been synthesized following a six-step linear sequence. Central to the approach employed is the formation of a 7-lithiated-2,4-dialkoxybenzothiazole intermediate obtained via a directed-lithiation/benzyne-mediated cyclization reaction. The incorporation of a tert-butyl ether residue into the cyclization precursor for the pivotal ring-closing step has been shown to significantly increase the efficiency of the reaction by the suppression of a competing directed ortho-lithiation reaction.

  DOI：

  10.1021/ol0518840

文献信息

• Catalytic Enantioselective Synthesis of Mariline A and Related Isoindolinones through a Biomimetic Approach
  作者：Chang Min、Yingfu Lin、Daniel Seidel

  DOI：10.1002/anie.201709182

  日期：2017.11.27

  The catalytic enantioselective synthesis of isoindolinones was achieved through the condensation of 2‐acyl‐benzaldehydes and anilines. In the presence of 1 mol % of a chiral phosphoric acid catalyst, reactions reach completion within 10 min and provide products with up to 98 % ee. Anilines with an ortho t‐butyl group form atropisomeric products, thereby enabling the simultaneous generation of axial

  异吲哚啉酮的催化对映选择性合成是通过2酰基苯甲醛和苯胺的缩合实现的。在1mol％的手性磷酸催化剂的存在下，反应在10分钟内完成，并提供具有高达98％ee的产物。具有邻叔丁基的苯胺形成阻转异构体产物，从而能够从两个非手性底物同时产生轴向和点手性。该方法被用于第一次合成的海水line。
• [EN] BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY<br/>[FR] DERIVES DE BENZOTHIAZOLE AYANT UNE ACTIVITE D'AGONISTE DU BETA-2-ADRENORECEPTEUR
  申请人：NOVARTIS AG

  公开号：WO2004016601A1

  公开（公告）日：2004-02-26

  Compounds of Formula (I) in free or salt or solvate form, wherein X has the meaning indicated in the specification, are useful for treating conditions that are prevented or alleviated by activation of the ß2-adrenoreceptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  公式(I)中的化合物以自由形式、盐或溶剂形式存在，其中X具有规范中指示的含义，可用于治疗通过激活β2-肾上腺素受体预防或缓解的症状。还描述了含有这些化合物的药物组合物以及制备这些化合物的方法。
• Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity
  申请人：Cuenoud Bernard

  公开号：US20060106075A1

  公开（公告）日：2006-05-18

  Compounds of formula (I) in free or salt or solvate form, wherein X has the meaning indicated in the specification, are useful for treating conditions that are prevented or alleviated by activation of the β 2 -adrenoreceptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  式(I)的化合物，包括自由形式、盐形式或溶剂合物形式，其中X的含义如规范中所示，可用于治疗通过激活β2-肾上腺素能受体预防或缓解的疾病。还描述了包含该化合物的制药组合物和制备该化合物的过程。
• QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION
  申请人：Otsubo Kenji

  公开号：US20100130546A1

  公开（公告）日：2010-05-27

  The present invention provides a quinolone compound represented by General Formula (1) or a salt thereof, wherein R 1 represents a hydrogen atom, etc.; R 2 represents a hydrogen atom, etc.; R 3 represents a phenyl group optionally being substituted with one or more substituents, etc.; R 4 represents a halogen atom; R 5 represents a hydrogen atom or halogen atom; R 6 represents a hydrogen atom; and R 7 represents a hydroxyl group, etc. The quinolone compound have a functional improvement effect, which suppresses progression of neurological dysfunction by inhibiting the chronic progression of Parkinson's disease or protecting dopamine neurons from the disease etiology, thereby prolonging the period before first administration begins.

  本发明提供了一种喹诺酮化合物，其由通式（1）或其盐所表示，其中R1表示氢原子等；R2表示氢原子等；R3表示苯基，该苯基可以选择性地被一个或多个取代基取代等；R4表示卤素原子；R5表示氢原子或卤素原子；R6表示氢原子；R7表示羟基等。该喹诺酮化合物具有功能改善效果，通过抑制帕金森病的慢性进展或保护多巴胺神经元免受疾病病因的影响，从而延长首次给药前的期间，抑制神经功能障碍的进展。
• BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY
  申请人：Novartis AG

  公开号：EP1529038A1

  公开（公告）日：2005-05-11